Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJC 1295 in HIV-Associated Visceral Obesity
NCT00267527Phase 2Terminated
- Sponsor
- ConjuChem
- Start
- Dec 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of CJC-1295 in Visceral obesity (3 arms), sponsored by ConjuChem. Primary endpoints: Efficacy of CJC 1295 at 12 weeks, Pharmacokinetics of CJC 1295 at 12 weeks and 2 more. Started Dec 2005; status: terminated.
02
Drugs
CJC-1295
03
Conditions
Visceral obesity
Beyond the preview
Go deeper on NCT00267527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267527.